70,801 Shares in Exelixis, Inc. (NASDAQ:EXEL) Bought by ExodusPoint Capital Management LP

ExodusPoint Capital Management LP acquired a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 70,801 shares of the biotechnology company’s stock, valued at approximately $2,358,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Motley Fool Asset Management LLC bought a new position in Exelixis during the 4th quarter valued at about $223,000. Trexquant Investment LP grew its stake in shares of Exelixis by 39.3% during the fourth quarter. Trexquant Investment LP now owns 595,146 shares of the biotechnology company’s stock valued at $19,818,000 after buying an additional 167,907 shares during the last quarter. Franklin Resources Inc. grew its stake in shares of Exelixis by 12.2% during the fourth quarter. Franklin Resources Inc. now owns 891,985 shares of the biotechnology company’s stock valued at $29,703,000 after buying an additional 97,342 shares during the last quarter. O Shaughnessy Asset Management LLC raised its holdings in shares of Exelixis by 8.5% in the fourth quarter. O Shaughnessy Asset Management LLC now owns 9,679 shares of the biotechnology company’s stock worth $322,000 after buying an additional 761 shares during the period. Finally, Schroder Investment Management Group lifted its stake in shares of Exelixis by 87.6% during the 4th quarter. Schroder Investment Management Group now owns 558,798 shares of the biotechnology company’s stock worth $18,831,000 after acquiring an additional 260,940 shares during the last quarter. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Insider Buying and Selling

In other news, Director Mary C. Beckerle sold 12,210 shares of the business’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $34.88, for a total transaction of $425,884.80. Following the sale, the director now owns 30,406 shares in the company, valued at approximately $1,060,561.28. The trade was a 28.65 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Christopher J. Senner sold 29,314 shares of the company’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $36.14, for a total transaction of $1,059,407.96. Following the transaction, the chief financial officer now owns 779,607 shares in the company, valued at approximately $28,174,996.98. This trade represents a 3.62 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 140,343 shares of company stock worth $5,177,234 in the last ninety days. 2.85% of the stock is owned by insiders.

Exelixis Stock Up 0.8 %

Shares of Exelixis stock opened at $34.84 on Tuesday. The company has a market cap of $9.75 billion, a P/E ratio of 19.68, a PEG ratio of 1.13 and a beta of 0.57. The firm’s 50 day moving average price is $35.94 and its 200-day moving average price is $33.70. Exelixis, Inc. has a 52-week low of $20.14 and a 52-week high of $40.02.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. As a group, equities research analysts forecast that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Morgan Stanley raised shares of Exelixis from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $30.00 to $40.00 in a research note on Monday, January 27th. Stifel Nicolaus lifted their price target on shares of Exelixis from $30.00 to $36.00 and gave the company a “hold” rating in a research note on Wednesday, February 12th. HC Wainwright reissued a “buy” rating and issued a $40.00 price objective on shares of Exelixis in a research note on Thursday, March 27th. Citigroup raised their price objective on Exelixis from $38.00 to $45.00 and gave the stock a “buy” rating in a report on Wednesday, February 12th. Finally, Piper Sandler upped their target price on Exelixis from $37.00 to $38.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $37.59.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.